Home Conference Coverage ASH Conference Coverage

ASH Conference Coverage

Venetoclax Resulted in High Efficacy in Patients With CLL With TP53 Disruption

More Than 20% of Patients With CLL Developed at Least 1 Second Primary Malignancy

Oral Anticancer Agent Therapy Adherence in Patients With CLL and Multiple Chronic Conditions

Clinical Outcomes and Management of COVID-19 in Patients With CLL

Racial Disparities Found in Patients With CLL Undergoing Targeted Therapy

Liso-cel Versus Standard of Care as Second-Line Therapy for Relapsed/Refractory LBCL

Anti-BCMA CAR T-Cell Therapy CT103A Provides Rapid, Durable Responses

Tisa-Cel Found Noninferior to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL

ZUMA-7: Benefits of Axi-Cel Persist Over Current Standard of Care in Aggressive B-Cell Lymphoma

Black Patients Are Severely Under-Represented in Pivotal CAR T-Cell Clinical Trials

Load more
Subscribe to RSS